China’s commercial health insurance sector is expanding its role in the country’s healthcare system as government-funded coverage comes under increasing strain from demographic shifts and rising medical costs.
Healthcare expenditure reached ¥9.06 trillion in 2023, up from 2014 at a compound annual growth rate of 9.9%. Spending accounted for 7.2% of GDP, compared to 5.5% in 2014. By contrast, developed countries such as the United States, Germany, and Japan reported higher ratios at 16.5%, 12.6%, and 11.4%, respectively.
Mandatory basic medical insurance in China covers over 95% of the population and has reduced out-of-pocket healthcare costs from 33.2% in 2014 to 27.3% in 2023. However, the fund’s annual surplus has decreased for two straight years, reaching ¥0.47 trillion in 2024. Factors contributing to this include an aging population, a declining worker-to-retiree ratio, expanded drug coverage, and lower employer contributions.
To address long-term viability, authorities have implemented volume-based drug procurement, updated the drug reimbursement list regularly, and adopted DRG (Diagnosis-Related Group) and DIP (Diagnosis Intervention Package) systems. These initiatives are designed to control reimbursement limits, introduce consistent treatment plans, and reduce inefficiencies.
As demand rises for healthcare services beyond basic government coverage, particularly among middle- and high-income households, commercial health insurance is gaining ground. Premiums reached US$133.9 billion in 2023, increasing at a 20% CAGR since 2014. Claims also rose from US$9.2 billion in 2014 to US$54 billion in 2023, accounting for 4.2% of total healthcare spending. The sector’s share of GDP rose to 0.7% from 0.2% over the same period.
Despite this growth, recent premium expansion has slowed to 8.2% in 2024, compared to a 20.5% CAGR during 2016-2019. Industry analysts point to intensified market competition, slower economic conditions, data limitations, and adverse selection risks.
Insurers are integrating DRG-based data and clinical pathways into product design and risk models. Encrypted, de-identified medical data, accessed through blockchain, is reducing underwriting time and accelerating claims processing. Value-based insurance models are also being explored to cover treatments outside standard reimbursement frameworks.
How should insurers evolve to meet China’s rising healthcare demand? Share your thoughts in the comments.
